论文部分内容阅读
目的:观察瑞格列奈(浮来迪)治疗2型糖尿病的临床疗效。方法:采用自身前后对照,对48例初次治疗的2型糖尿病患者在合理饮食、运动、定期监测措施基础上,给予浮来迪1.0 mg,3次/d,饭前服用,共观察12周。结果:治疗12周后患者空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1C)均明显下降(P<0.01);甘油三脂下降(P<0.01)。结论:浮来迪具有良好的控制血糖作用,可降甘油三脂,不良反应较轻,具有良好的耐受性。
Objective: To observe the clinical efficacy of repaglinide in treating type 2 diabetes mellitus. Methods: Forty-eight patients with type 2 diabetes who were treated for the first time were given Fufangdi 1.0 mg three times daily for 12 weeks on the basis of reasonable diet, exercise and regular monitoring measures. Results: Fasting plasma glucose (FBG), postprandial blood glucose (PBG) and HbA1C were significantly decreased (P <0.01) and triglyceride decreased (P <0.01) after treatment for 12 weeks. Conclusion: Floydie has a good control of blood glucose, triglyceride can be reduced, mild adverse reactions, with good tolerance.